188 related articles for article (PubMed ID: 17090195)
1. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
Jaffee IM; Rahmani M; Singhal MG; Younes M
Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
[TBL] [Abstract][Full Text] [Related]
2. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.
Rabban JT; Lerwill MF; McCluggage WG; Grenert JP; Zaloudek CJ
Int J Gynecol Pathol; 2009 Jan; 28(1):41-8. PubMed ID: 19047909
[TBL] [Abstract][Full Text] [Related]
3. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids.
Saqi A; Alexis D; Remotti F; Bhagat G
Am J Clin Pathol; 2005 Mar; 123(3):394-404. PubMed ID: 15716236
[TBL] [Abstract][Full Text] [Related]
5. IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver.
Denby KS; Briones AJ; Bourne PA; Spaulding BO; Lu D; Fischer-Colbrie R; Qu Z; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):573-9. PubMed ID: 22495359
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
Srivastava A; Hornick JL
Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
[TBL] [Abstract][Full Text] [Related]
7. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites.
Erickson LA; Papouchado B; Dimashkieh H; Zhang S; Nakamura N; Lloyd RV
Endocr Pathol; 2004; 15(3):247-52. PubMed ID: 15640551
[TBL] [Abstract][Full Text] [Related]
8. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors.
La Rosa S; Rigoli E; Uccella S; Chiaravalli AM; Capella C
Virchows Arch; 2004 Sep; 445(3):248-54. PubMed ID: 15517368
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
10. Galectin-4 expression in carcinoid tumors.
Rumilla KM; Erickson LA; Erickson AK; Lloyd RV
Endocr Pathol; 2006; 17(3):243-9. PubMed ID: 17308361
[TBL] [Abstract][Full Text] [Related]
11. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
12. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
Fan Z; Li J; Dong B; Huang X
Clin Cancer Res; 2005 Sep; 11(17):6162-70. PubMed ID: 16144916
[TBL] [Abstract][Full Text] [Related]
13. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
14. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
Werling RW; Yaziji H; Bacchi CE; Gown AM
Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal carcinoids: characterization by site of origin and hormone production.
Onaitis MW; Kirshbom PM; Hayward TZ; Quayle FJ; Feldman JM; Seigler HF; Tyler DS
Ann Surg; 2000 Oct; 232(4):549-56. PubMed ID: 10998653
[TBL] [Abstract][Full Text] [Related]
16. Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors.
Al-Khafaji B; Noffsinger AE; Miller MA; DeVoe G; Stemmermann GN; Fenoglio-Preiser C
Hum Pathol; 1998 Sep; 29(9):992-9. PubMed ID: 9744317
[TBL] [Abstract][Full Text] [Related]
17. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays.
Moskaluk CA; Zhang H; Powell SM; Cerilli LA; Hampton GM; Frierson HF
Mod Pathol; 2003 Sep; 16(9):913-9. PubMed ID: 13679455
[TBL] [Abstract][Full Text] [Related]
18. Expression of cadherin 17 in well-differentiated neuroendocrine tumours.
Snow AN; Mangray S; Lu S; Clubwala R; Li J; Resnick MB; Yakirevich E
Histopathology; 2015 Jun; 66(7):1010-21. PubMed ID: 25388236
[TBL] [Abstract][Full Text] [Related]
19. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum.
Stinner B; Kisker O; Zielke A; Rothmund M
World J Surg; 1996 Feb; 20(2):183-8. PubMed ID: 8661815
[TBL] [Abstract][Full Text] [Related]
20. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]